Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Use of antidepressants and risk of epithelial ovarian cancer

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Testicular cancer incidence predictions in Europe 2010–2035: A rising burden despite population ageing

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Tibolone and risk of gynecological hormone sensitive cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Does HPV status influence survival after vulvar cancer?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Shared heritability and functional enrichment across six solid cancers

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk of CIN2+ following a diagnosis of genital warts: a nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk of breast cancer among women with benign ovarian tumors: a Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Publisher Correction: Shared heritability and functional enrichment across six solid cancers

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Antidepressants are widely prescribed among women to treat depression and anxiety disorders, but studies of their effects on gynecological cancer risk are sparse. We assessed associations between various antidepressants and risk of epithelial ovarian cancer. By using Danish nationwide registers, we identified all women (cases) aged 30-84 years with incident epithelial (serous, endometrioid, clear cell or mucinous) ovarian cancer during 2000-2011 (n = 4,103) and matched each case to 20 population controls (n = 58,706) by risk-set matching. Data on drug use (including tricyclic and related antidepressants, selective serotonin reuptake inhibitors, other antidepressants, and potential confounder drugs), medical and reproductive history and socioeconomic parameters, were obtained from nationwide registries. We used conditional logistic regression models to estimate adjusted odds ratios (ORs) and two-sided 95% confidence intervals (CIs) for epithelial ovarian cancer associated with antidepressive drug use. Compared with non-use, use of selective serotonin reuptake inhibitors was associated with a decreased risk of ovarian cancer (OR, 0.85; 95% CI, 0.74-0.96), whereas the associations for other antidepressants were close to unity [tricyclic and related antidepressants: OR, 0.99 (95% CI, 0.78-1.26); other antidepressants: OR, 1.05 (95% CI, 0.76-1.46)]. For individual types of SSRI, reduced ORs were observed for citalopram OR, 0.78 (95% CI, 0.66-0.93), paroxetine 0.79 (95% CI, 0.56-1.12) and sertraline 0.80 (95% CI, 0.60-1.08). Among postmenopausal women, the inverse association was restricted to users of menopausal hormone therapy. In conclusion, use of selective serotonin reuptake inhibitors was associated with a decreased risk of epithelial ovarian cancer; thereby implying potential chemopreventive properties of these drugs.

Original languageEnglish
JournalRadiation Oncology Investigations
Volume141
Issue number11
Pages (from-to)2197-2203
ISSN0020-7136
DOIs
Publication statusPublished - 1 Dec 2017

    Research areas

  • Adult, Aged, Aged, 80 and over, Antidepressive Agents, Case-Control Studies, Denmark, Female, Humans, Incidence, Logistic Models, Middle Aged, Neoplasms, Glandular and Epithelial, Odds Ratio, Ovarian Neoplasms, Registries, Serotonin Uptake Inhibitors, Journal Article

ID: 52206623